New eye drops could help kids with lazy eye that Won't go away
NCT ID NCT07554131
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding echothiophate iodide eye drops to standard atropine therapy can improve vision in children aged 3 to 18 with refractory amblyopia (lazy eye that hasn't improved with standard treatment). Twenty participants will use atropine nightly for 12 weeks, and if no improvement after 4 weeks, they'll also use echothiophate drops in the weaker eye for 8 weeks. The goal is to see if this combination can boost visual acuity and depth perception.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Echothiophate iodide eye drops
- What this could lead to
- If it works, this could offer a new treatment option for children with lazy eye that hasn't improved with standard therapy, potentially improving vision and depth perception.
- What could go wrong
- This is a small early-phase trial with only 20 participants, so results may not apply to all children. The drug may cause side effects like eye irritation or blurred vision, and it's unclear if benefits will last after stopping treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children/adolescents between 3 and \<18 years old with amblyopia who are currently undergoing atropine treatment who are deemed to no longer be improving. * Diagnosis of amblyopia associated with strabismus, anisometropia, or mixed types (as defined by previous PEDIG studies). * Wearing appropriate spectacle correction based on cycloplegic refraction using PEDIG protocol recommendations. * Currently undergoing atropine treatment (either 2x a week or every other day) with visual acuity in the amblyopic eye that has not improved with atropine treatment from participant's previous visit. * Cycloplegic refraction that has been completed within 6 months of enrollment. * Ability to measure visual acuity using standardized testing protocols. * Visual acuity in the amblyopic eye 20/40 to 20/100. Visual acuity in the non-amblyopic eye 20/30 or better with intraocular difference greater than or equal to 2 lines. Exclusion Criteria: * Existing ocular conditions likely to interfere with treatment response (e.g., congenital cataract history, corneal opacities/scars, ptosis, retinal diseases). * Neurologic or systemic conditions that impact vision. * Severe developmental delays that might impact treatment adherence and outcome evaluation. * Current use of prisms or bifocals. * Active uveal inflammation or history of angle-closure glaucoma. * Concurrent use of other anticholinesterase medications. * Anticipated surgical procedures during the study period. * Prior surgical interventions for ocular conditions that could interfere with study outcomes. * Myopia with spherical equivalent \>6D. * Any contraindications to the components of the medicine to be used in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Refractory amblyopia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dean McGee Eye Institute
Oklahoma City, Oklahoma, 73104, United States